Zerbor / Shutterstock.com
US pharmaceutical company Strategic Science and Technologies (SST) has signed an option agreement with “one of the world’s largest over-the-counter (OTC) healthcare companies” to commercialise one of its ibuprofen products.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Strategic Science and Technologies; FDA; Ibuprofen
